作者
Xiao-Yan Chu, Kelly Bleasby, Jocelyn Yabut, Xiaoxin Cai, Grace Hoyee Chan, Michael J Hafey, Shiyao Xu, Arthur J Bergman, Matthew P Braun, Dennis C Dean, Raymond Evers
发表日期
2007/5/1
期刊
Journal of Pharmacology and Experimental Therapeutics
卷号
321
期号
2
页码范围
673-683
出版商
American Society for Pharmacology and Experimental Therapeutics
简介
Sitagliptin, a selective dipeptidyl peptidase 4 inhibitor recently approved for the treatment of type 2 diabetes, is excreted into the urine via active tubular secretion and glomerular filtration in humans. In this report, we demonstrate that sitagliptin is transported by human organic anion transporter hOAT3 (Km = 162 μM), organic anion transporting polypeptide OATP4C1, and multidrug resistance (MDR) P-glycoprotein (Pgp), but not by human organic cation transporter 2 hOCT2, hOAT1, oligopeptide transporter hPEPT1, OATP2B1, and the multidrug resistance proteins MRP2 and MRP4. Our studies suggested that hOAT3, OATP4C1, and MDR1 Pgp might play a role in transporting sitagliptin into and out of renal proximal tubule cells, respectively. Sitagliptin did not inhibit hOAT1-mediated cidofovir uptake, but it showed weak inhibition of hOAT3-mediated cimetidine uptake (IC50 = 160 μM). hOAT3-mediated sitagliptin …
引用总数
200720082009201020112012201320142015201620172018201920202021202220232024511910171816151116151116515742